C
Gilead Sciences, Inc. GILD
$65.06 $2.273.62%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
52-Week Range
P/E (TTM)
EPS (TTM)
C
Hold 5/14/2024Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C- from C on 5/14/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.1291 to -$3.344, net income declined 391.81% from $1.43B to -$4.17B, and EBIT declined 23.34% from $3B to $2.3B.
C
Hold 5/2/2024Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C from C+ on 5/2/2024 due to a decline in the volatility index, total return index and growth index.
C
Hold 4/12/2024Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 4/12/2024 due to a decline in the volatility index, valuation index and total return index.
B
Buy 2/21/2024Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to B- from B on 2/21/2024 due to a decline in the total return index and volatility index.
B
Buy 2/6/2024Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B from B- on 2/6/2024 due to an increase in the valuation index and dividend index.
B
Buy 1/22/2024Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to B- from B on 1/22/2024 due to a decline in the valuation index, total return index and dividend index.
B
Buy 11/24/2023Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B from B- on 11/24/2023 due to an increase in the volatility index, valuation index and dividend index.
B
Buy 11/8/2023Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to B- from B on 11/8/2023 due to a large decline in the growth index and volatility index. Operating cash flow declined 24.94% from $2.34B to $1.76B.
B
Buy 11/7/2023Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B from B- on 11/7/2023 due to a noticeable increase in the volatility index, total return index and solvency index.
B
Buy 10/16/2023Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 10/16/2023 due to an increase in the volatility index, solvency index and valuation index.
C
Hold 8/30/2023Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 8/30/2023 due to a decline in the volatility index.
B
Buy 8/15/2023Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 8/15/2023 due to a major increase in the growth index and efficiency index. Operating cash flow increased 34.06% from $1.74B to $2.34B, total revenue increased 3.89% from $6.35B to $6.6B, and earnings per share increased from $0.8 to $0.83.
C
Hold 7/7/2023Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 7/7/2023 due to a decline in the volatility index and total return index.
B
Buy 5/5/2023Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 5/5/2023 due to a noticeable increase in the growth index, valuation index and efficiency index.
C
Hold 4/6/2023Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 4/6/2023 due to a major decline in the total return index and volatility index.
B
Buy 2/23/2023Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to B- from B on 2/23/2023 due to a significant decline in the growth index and dividend index. EBIT declined 27.42% from $3.32B to $2.41B, operating cash flow declined 10.34% from $2.86B to $2.57B, and earnings per share declined from $1.42 to $1.2998.
B
Buy 11/25/2022Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B from B- on 11/25/2022 due to a major increase in the total return index, growth index and efficiency index. Operating cash flow increased 58.88% from $1.8B to $2.86B, net income increased 56.38% from $1.14B to $1.79B, and earnings per share increased from $0.91 to $1.42.
B
Buy 10/31/2022Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 10/31/2022 due to an increase in the total return index and volatility index.
C
Hold 10/11/2022Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C+ from C on 10/11/2022 due to a noticeable increase in the volatility index, growth index and efficiency index. Earnings per share increased from $0.0151 to $0.91, net income increased 5,921.05% from $19M to $1.14B, and total capital increased 0.67% from $46.12B to $46.43B.
C
Hold 3/22/2022Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C from C+ on 3/22/2022 due to a decline in the total return index.
C
Hold 3/21/2022Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 3/21/2022 due to a decline in the total return index and volatility index.
B
Buy 3/2/2022Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 3/2/2022 due to an increase in the volatility index, efficiency index and dividend index.
C
Hold 2/11/2022Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 2/11/2022 due to a decline in the total return index and volatility index.
B
Buy 1/7/2022Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 1/7/2022 due to an increase in the total return index.
C
Hold 12/21/2021Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 12/21/2021 due to a decline in the valuation index and volatility index.
B
Buy 11/29/2021Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 11/29/2021 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $1.21 to $2.05, EBIT increased 57.39% from $2.34B to $3.69B, and operating cash flow increased 40.46% from $2.32B to $3.25B.
C
Hold 10/15/2021Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C+ from B- on 10/15/2021 due to a decline in the volatility index.
B
Buy 9/20/2021Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to B- from C+ on 9/20/2021 due to an increase in the volatility index and total return index.
C
Hold 8/6/2021Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C+ from C on 8/6/2021 due to a significant increase in the valuation index, growth index and volatility index.
C
Hold 5/3/2021Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C from C- on 5/3/2021 due to a large increase in the growth index, efficiency index and valuation index. Net income increased 330.83% from $360M to $1.55B, earnings per share increased from $0.2869 to $1.2359, and EBIT increased 23.46% from $3.17B to $3.92B.
C
Hold 8/14/2020Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C- from C on 8/14/2020 due to a significant decline in the valuation index, total return index and efficiency index. Net income declined 315.28% from $1.55B to -$3.34B, and total capital declined 8.71% from $46.28B to $42.24B.
C
Hold 7/13/2020Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C from C+ on 7/13/2020 due to a decline in the volatility index, valuation index and dividend index.
C
Hold 5/26/2020Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C+ from C on 5/26/2020 due to a noticeable increase in the total return index, valuation index and volatility index.
C
Hold 5/8/2020Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C from C+ on 5/8/2020 due to a noticeable decline in the growth index, valuation index and solvency index. Operating cash flow declined 44.34% from $2.58B to $1.44B, earnings per share declined from $2.125 to $1.22, and total revenue declined 5.63% from $5.88B to $5.55B.
C
Hold 4/17/2020Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C+ from C on 4/17/2020 due to a large increase in the total return index, solvency index and growth index. Earnings per share increased from -$0.92 to $2.125, EBIT increased 228.51% from -$1.47B to $1.89B, and debt to equity declined from 1.2 to 1.1.
C
Hold 1/27/2020Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C from C- on 1/27/2020 due to an increase in the valuation index, volatility index and total return index.
C
Hold 12/18/2019Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C- from C on 12/18/2019 due to a decline in the volatility index and valuation index.
C
Hold 11/29/2019Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C from C- on 11/29/2019 due to an increase in the volatility index and total return index.
C
Hold 11/12/2019Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C- from C on 11/12/2019 due to a major decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.47 to -$0.92, net income declined 161.97% from $1.88B to -$1.17B, and EBIT declined 160.62% from $2.43B to -$1.47B.
C
Hold 9/6/2019Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C from C- on 9/6/2019 due to an increase in the volatility index, total return index and valuation index.
C
Hold 5/15/2019Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C- from D+ on 5/15/2019 due to a noticeable increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.0023 to $1.54, EBIT increased 13.9% from $1.96B to $2.24B, and the quick ratio increased from 3.21 to 3.44.
D
Sell 4/23/2019Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to D+ from C- on 4/23/2019 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from $1.6 to $0.0023, EBIT declined 25.12% from $2.62B to $1.96B, and debt to equity increased from 1.19 to 1.28.
C
Hold 2/26/2019Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C- from D+ on 2/26/2019 due to an increase in the volatility index and valuation index.
D
Sell 1/11/2019Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to D+ from C- on 1/11/2019 due to a substantial decline in the valuation index, total return index and solvency index.
C
Hold 6/29/2018Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C- from D+ on 6/29/2018 due to an increase in the total return index.
D
Sell 6/8/2018Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to D+ from C- on 6/8/2018 due to a decline in the total return index, volatility index and valuation index.
C
Hold 3/2/2018Downgrade
Gilead Sciences, Inc. (GILD) was downgraded to C- from C on 3/2/2018 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $2.06 to -$2.9572, debt to equity increased from 1.18 to 1.64, and EBIT declined 38.64% from $3.81B to $2.34B.
C
Hold 8/30/2017Upgraded
Gilead Sciences, Inc. (GILD) was upgraded to C from C- on 8/30/2017 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 2.26 to 3.07, operating cash flow increased 20.55% from $2.93B to $3.53B, and earnings per share increased from $2.05 to $2.33.
C
Hold 2/6/2017Downgrade
Gilead Sciences Inc. (GILD) was downgraded to C- from C on 2/6/2017 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 12.35% from $4.94B to $4.33B, total revenue declined 3.55% from $7.78B to $7.5B, and earnings per share declined from $2.58 to $2.49.
C
Hold 10/5/2016Downgrade
Gilead Sciences Inc. (GILD) was downgraded to C from C+ on 10/5/2016 due to a decline in the volatility index, total return index and valuation index.
C
Hold 9/20/2016Upgraded
Gilead Sciences Inc. (GILD) was upgraded to C+ from C on 9/20/2016 due to an increase in the volatility index and valuation index.
C
Hold 8/12/2016Downgrade
Gilead Sciences Inc. (GILD) was downgraded to C from C+ on 8/12/2016 due to a decline in the volatility index and total return index.
C
Hold 6/13/2016Downgrade
Gilead Sciences Inc. (GILD) was downgraded to C+ from B- on 6/13/2016 due to a significant decline in the growth index, solvency index and volatility index. Debt to equity increased from 1.2 to 1.64, the quick ratio declined from 2.07 to 1.33, and earnings per share declined from $3.185 to $2.53.
B
Buy 3/28/2016Upgraded
Gilead Sciences Inc. (GILD) was upgraded to B- from C+ on 3/28/2016 due to an increase in the volatility index.
C
Hold 3/11/2016Downgrade
Gilead Sciences Inc. (GILD) was downgraded to C+ from B+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
B
Buy 3/4/2016Downgrade
Gilead Sciences Inc. (GILD) was downgraded to B+ from A- on 3/4/2016 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 0.54% from $5.59B to $5.56B.
A
Buy 10/20/2015Downgrade
Gilead Sciences Inc. (GILD) was downgraded to A- from A on 10/20/2015 due to a decline in the total return index, volatility index and valuation index.
A
Buy 10/6/2015Downgrade
Gilead Sciences Inc. (GILD) was downgraded to A from A+ on 10/6/2015 due to a noticeable decline in the volatility index, solvency index and growth index. The quick ratio declined from 2.6 to 1.56, and debt to equity increased from 0.72 to 0.75.
A
Buy 5/8/2015Upgraded
Gilead Sciences Inc. (GILD) was upgraded to A+ from A- on 5/8/2015 due to a noticeable increase in the valuation index, volatility index and growth index. Operating cash flow increased 88.73% from $3.02B to $5.7B, earnings per share increased from $2.1884 to $2.76, and EBIT increased 14.12% from $4.71B to $5.37B.
A
Buy 1/16/2015Downgrade
Gilead Sciences Inc. (GILD) was downgraded to A- from A on 1/16/2015 due to a large decline in the total return index, growth index and solvency index. Earnings per share declined from $2.2 to $1.67, the quick ratio declined from 1.96 to 1.51, and EBIT declined 21.16% from $4.41B to $3.48B.
A
Buy 8/6/2014Upgraded
Gilead Sciences Inc. (GILD) was upgraded to A from A- on 8/6/2014 due to a noticeable increase in the valuation index, total return index and solvency index. The quick ratio increased from 1.64 to 1.96, and debt to equity declined from 0.73 to 0.59.
A
Buy 5/9/2014Upgraded
Gilead Sciences Inc. (GILD) was upgraded to A- from B on 5/9/2014 due to a substantial increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.4642 to $1.33, EBIT increased 164.67% from $1.15B to $3.04B, and operating cash flow increased 115.75% from $726.79M to $1.57B.
Weiss Ratings